The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing

Daniela Frasca1,2,4✉, Lisa Reidy3,4, Maria Romero1, Alain Diaz1, Carolyn Cray3, Kristin Kahl3 and Bonnie B. Blomberg1,2

© The Author(s) 2021

BACKGROUND/OBJECTIVES: Obesity decreases the secretion of SARS-CoV-2-specific IgG antibodies in the blood of COVID-19 patients. How obesity impacts the quality of the antibodies secreted, however, is not understood. Therefore, the objective of this study is to evaluate the presence of neutralizing versus autoimmune antibodies in COVID-19 patients with obesity.

SUBJECTS/METHODS: Thirty serum samples from individuals who tested positive for SARS-CoV-2 infection by RT-PCR were collected from inpatient and outpatient settings. Of these, 15 were lean (BMI < 25) and 15 were obese (BMI ≥ 30). Control serum samples were from 30 uninfected individuals, age-, gender-, and BMI-matched, recruited before the current pandemic. Neutralizing and autoimmune antibodies were measured by ELISA. IgG autoimmune antibodies were specific for malondialdehyde (MDA), a marker of oxidative stress and lipid peroxidation, and for adipocyte-derived protein antigens (AD), markers of virus-induced cell death in the obese adipose tissue.

RESULTS: SARS-CoV-2 infection induces neutralizing antibodies in all lean but only in few obese COVID-19 patients. SARS-CoV-2 infection also induces anti-MDA and anti-AD autoimmune antibodies more in lean than in obese patients as compared to uninfected controls. Serum levels of these autoimmune antibodies, however, are always higher in obese versus lean COVID-19 patients. Moreover, because the autoimmune antibodies found in serum samples of COVID-19 patients have been correlated with serum levels of C-reactive protein (CRP), a general marker of inflammation, we also evaluated the association of anti-MDA and anti-AD antibodies with serum CRP and found a positive association between CRP and autoimmune antibodies.

CONCLUSIONS: Our results highlight the importance of evaluating the quality of the antibody response in COVID-19 patients with obesity, particularly the presence of autoimmune antibodies, and identify biomarkers of self-tolerance breakdown. This is crucial to protect this vulnerable population at higher risk of responding poorly to infection with SARS-CoV-2 than lean controls.

International Journal of Obesity; https://doi.org/10.1038/s41366-021-01016-9

INTRODUCTION

The novel single-stranded RNA coronavirus SARS-CoV-2 (severe acute respiratory syndrome corona virus-2) emerged in the last months of 2019, caused the worldwide coronavirus disease 2019 (COVID-19) pandemic, and was responsible for different clinical manifestations ranging from mild disease to severe respiratory tract infections, multigorgan failure, and death. The severe manifestations of the disease are associated with an exuberant inflammatory response and the development of a condition known as cytokine storm [1]. Published data have indicated that inflammmaging, the chronic low-grade systemic inflammation [2], is a major cause of the cellular and molecular changes induced by SARS-CoV-2 and can be responsible for the highest number of deaths [3]. In addition, inflammmaging induces chronic immune activation (IA) and dysfunctional immunity [4].

Resolution of SARS-CoV-2 infection requires both innate and adaptive immune responses that lead to the clearance and elimination of the virus from the organism. B cells contribute to this process by producing neutralizing antibodies that prevent the spread of infectious virions, control virus dissemination, and reduce tissue damage. Neutralizing antibodies generated against the Spike glycoprotein of the SARS-CoV-1 in the 2002–2003 pandemic have shown efficacy in protecting from severe disease [5]. Moreover, during the current pandemic, it has been shown that neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2, found in plasma from convalescent COVID-19 patients, induced fast recovery when transfused into critically ill patients [6–8].

Obesity is an inflammatory condition associated with inflammmaging and chronic IA, contributing to functional impairment of immune cells, and decreased immunity. Obese individuals have been shown to respond poorly to infections [9–11], vaccination [12–14], and therapies for autoimmune conditions [15]. Therefore, obesity represents an additional risk factor for COVID-19 patients. A strong association between obesity, obesity-associated comorbidities, and severe outcomes of COVID-19 has indeed been

1Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA. 2Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. 3Department of Pathology & Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 4These authors contributed equally: Daniela Frasca, Lisa Reidy. ✉Email: dfrasca@med.miami.edu

Received: 19 July 2021 Revised: 20 October 2021 Accepted: 25 October 2021
Published online: 07 November 2021
shown [16], with adult COVID-19 symptomatic patients with Body Mass Index (BMI) >30 showing higher admission to acute and critical care compared to lean and overweight individuals (BMI < 30) [17]. These results have been confirmed in part in a multi-site prospective cohort of non-hospitalized individuals in which obesity was found to be associated with the presence of multiple COVID-19 symptoms [18] However, in this cohort obesity was not associated with increased risk of infection.

We have previously evaluated the effects of obesity on the secretion of SARS-CoV-2-specific immunoglobulin G (IgG) antibodies in the blood of lean and overweight/obese COVID-19 patients, and we have shown that SARS-CoV-2 IgG antibodies are negatively associated with BMI in COVID-19 patients, as expected based on the known effects of overweight/obesity on humoral immunity [19]. In this study, we have evaluated the quality of the antibody response in lean (BMI < 25) and obese (BMI > 30) COVID-19 patients, as compared to age-, gender-, and BMI-matched uninfected controls, without previous history of autoimmunity. It has been recently shown that the sera of adult COVID-19 patients contain antibodies with autoimmune specificities [20]. We measured the presence of neutralizing antibodies and autoimmune antibodies specific for malondialdehyde (MDA), which is used as a marker of oxidative stress and lipid peroxidation, and for adipocyte-derived protein antigens (AD), established markers of cell death in the obese adipose tissue (AT). This study included uninfected controls since obesity per se is associated with the secretion of autoimmune antibodies, as previously demonstrated [21–23]. We hypothesized that SARS-CoV-2 infection in COVID-19 patients with obesity induces oxidative stress and tissue damage, leading to cell death and release of intracellular antigens that are not known to be immunogenic autoantigens, and more in obese than in lean patients.

MATERIALS/SUBJECTS AND METHODS

Participants

Experiments were performed using serum samples isolated from individuals who tested positive for SARS-CoV-2 RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) of nasopharyngeal swab samples. Only serum samples were collected from patients, and samples used in this study were discarded clinical samples, only taken for routine clinical care purposes. Samples were de-identified before being used in this study. In total, 30 serum samples from individuals tested positive for SARS-CoV-2 infection by RT-PCR, 15 lean (BMI < 25) and 15 obese (BMI ≥ 30), were collected from both inpatient and outpatient settings and frozen until testing was performed. Both lean and obese patients had multiple respiratory symptoms (high fever, cough, shortness of breath, hypoxia), as evaluated at the time of hospital admission, but none was admitted to Intensive Care Unit. The research was approved and reviewed by the Institutional Review Board (IRB, protocol #20200504, PI Dr. Reidy) at the University of Miami, which reviews all human research conducted under the auspices of the University of Miami.

Control serum samples were from 30 uninfected individuals, age-, gender-, and BMI-matched, recruited at the University of Miami before the current pandemic (IRB, protocols #20070481 and #20160542, PI Dr. Frasca). Both lean and obese uninfected controls were screened for diseases known to alter the immune response or for consumption of medications that could alter the immune response. We excluded subjects with autoimmune diseases, congestive heart failure, cardiovascular disease, chronic renal failure, malignancies, renal or hepatic diseases, infectious disease, trauma or surgery, pregnancy, or documented current substance and/or alcohol abuse.

The characteristics of COVID-19 patients and controls are in Table 1. Both COVID-19 patients and uninfected controls were without prior history of autoimmunity.

Table 1. Characteristics of enrolled participants.

|                | Uninfected | SARS-CoV-2 infected |
|----------------|------------|---------------------|
| Age, mean±SE   |            |                     |
| Lean           | 53 ± 4     | 64 ± 9\(^d\)        |
| Obese          | 50 ± 2     | 55 ± 4\(^d\)        |
| BMI, mean±SE   |            |                     |
| Lean           | 22 ± 1     | 37 ± 2\(^c\)        |
| Obese          | 37 ± 2     | 32 ± 2\(^c\)        |
| Females        |            |                     |
| Lean           | 7          | 8                   |
| Obese          | 8          | 7                   |

\(^{a}\) Mean comparison of the ages in lean uninfected versus SARS-CoV-2-infected: \(p = 0.0973\).

\(^{b}\) Mean comparison of the ages in obese uninfected versus SARS-CoV-2-infected: \(p = 0.8094\).

\(^{c}\) Mean comparison of BMI of lean and obese uninfected: \(p < 0.0001\).

\(^{d}\) Mean comparison of BMI of lean and obese SARS-CoV-2-infected: \(p < 0.0001\).

SARS-CoV-2 tests

SARS-CoV-2 RNA was detected by RT-PCR of nasopharyngeal swab samples. RT-PCR tests were performed at the clinical laboratories of the Department of Pathology & Laboratory Medicine using either the Diasorin or the BDMax assay and reagents. Depending on submission type (symptomatic or asymptomatic), the sample was assigned and tested per the manufacturer guidelines.

Enzyme-linked immunosorbent assay (ELISA) to measure Spike-specific IgG antibodies

Serum IgG antibodies against SARS-CoV-2 Spike protein were measured by an ELISA developed and standardized in our laboratory [19]. Briefly, 96-well microplates (Immulon 4HBX, Thermo Scientific) were coated with recombinant NCP-CoV (2019-nCoV) Spike protein (S1 + S2 ECD) (Sino Biological #40589-V08B1) at 2 µg/mL for 1 h at room temperature. Plates were then washed with Tween-20 0.05% in phosphate-buffered saline (PBS) (PBST) and blocked with assay buffer (1% bovine serum albumin (BSA) in PBS) for 1 h at 37°C. After blocking, all subsequent steps were performed by a DYNEX DS2® Automated ELISA system (DYNEX Technologies, Chantilly, VA, USA). First, serum samples diluted at 1:50,000 in assay buffer were added in duplicate and plates were incubated for 2 h. Next, plates were washed with PBST and 100 µL per well of a peroxidase-conjugated goat anti-human IgG (Jackson Immunoresearch #109-036-098), diluted 1:10,000 in assay buffer, were added. After 1 h incubation, plates were washed, and a stabilized 3,3',5,5'-tetramethylbenzidine (TMB) substrate (Sigma) was added to the wells. The enzymatic reaction was stopped after 20 min with a stop solution (1 M sulfuric acid), and absorbance at 450 nm was read by the DYNEX DS2 instrument.

Neutralizing antibodies were measured by the cPass neutralization ELISA assay, a surrogate plaque reducing neutralization test using the DYNEX Agility® Automated ELISA system. The kit relies on the disruption of the protein–protein interaction between receptor-binding domain-horseradish peroxidase (RBD-HRP) and human angiotensin-converting enzyme 2 (hACE2) by neutralizing antibodies against SARS-CoV-2. First, the samples are preincubated with the RBD-HRP to allow interaction and binding of the antibodies. The sample is then added to the precoated hACE2 protein-coated plate. The plate is then washed, and then TMB is added, producing the blue color. The stop solution is then added, and the wells read at 450 nm. A calibration curve is generated using the cPass standard using the established concentration, and sample results are calculated from the interpolated standard curve.

ELISA to measure autoimmune antibodies

To measure MDA-specific IgG antibodies, ELISA plates were coated with MDA-modified BSA protein (MDA-BSA, MyBioSource MBS390120), at the concentration of 10 µg/mL. Control ELISA plates were coated with BSA at a concentration of 10 µg/mL.
We evaluated the presence of IgG antibodies with two auto-controls, lean and obese COVID-19 patients, as compared to uninfected controls. Results in Fig. 3 show that SARS-CoV-2 infection significantly increases serum levels of anti-MDA IgG antibodies (Fig. 3A) and anti-AD IgG antibodies (Fig. 3B) in both lean and obese patients, with a greater increase in lean versus obese patients. Fold increases in lean versus obese were 3.1 versus 1.6 for anti-MDA IgG antibodies and 6.4 versus 1.5 for anti-AD IgG antibodies. However, serum levels of all these antibodies were always higher in obese versus lean patients. Statistical analyses
We used one-way analysis of variance to examine differences between the four groups of participants (uninfected lean and obese, COVID lean and obese). Group-wise differences were analyzed afterward with Bonferroni’s multiple-comparisons test, with \( p < 0.05 \) set as a criterion for significance. \( F \) and \( p \) values generated after mixed-effects analyses were calculated and are reported in each figure legend. We used Student’s t tests (two-tailed) to examine differences between two groups. We used bivariate Pearson’s correlation analyses to examine relationships between variables. GraphPad Prism version 8.4.3 software was used to construct all graphs.

RESULTS
Evaluation of Spike-specific IgG antibodies in serum samples of lean and obese COVID-19 patients, as compared to uninfected controls
The results for Spike-specific IgG antibodies in serum samples of 30 COVID-19 patients and 30 uninfected controls, age-, gender-, and BMI-matched, are shown in Fig. 1. Antibodies were measured by an ELISA previously developed and standardized in our laboratory [19]. Results show significantly lower levels of Spike-specific IgG antibodies in obese versus lean COVID-19 patients, confirming our published findings that Spike-specific IgG antibodies in serum are negatively associated with BMI in COVID-19 patients [19]. In addition, spike-specific IgG antibodies were detected at extremely low levels in serum samples isolated from uninfected lean and obese age-, gender-, and BMI-matched participants recruited before the pandemic.

Evaluation of Spike-specific neutralizing IgG antibodies in serum samples of lean and obese COVID-19 patients
Results in Fig. 2 show that neutralizing antibodies were present in serum samples of all lean COVID-19 patients, whereas only a few obese COVID-19 patients had neutralizing antibodies.

Evaluation of autoimmune IgG antibodies in serum samples of lean and obese COVID-19 patients, as compared to uninfected controls
We evaluated the presence of IgG antibodies with two auto-immune specificities in serum samples of lean and obese COVID-19 patients as compared to uninfected controls. Results in Fig. 3 show that SARS-CoV-2 infection significantly increases serum levels of anti-MDA IgG antibodies (Fig. 3A) and anti-AD IgG antibodies (Fig. 3B) in both lean and obese patients, with a greater increase in lean versus obese patients. Fold increases in lean versus obese were 3.1 versus 1.6 for anti-MDA IgG antibodies and 6.4 versus 1.5 for anti-AD IgG antibodies. However, serum levels of all these antibodies were always higher in obese versus lean COVID-19 patients and uninfected controls.

Association of autoimmune IgG antibodies with CRP
We measured the association of anti-MDA and anti-AD with serum CRP, a marker of inflammation previously found to be positively associated with autoimmune antibodies [20]. Results in Fig. 4 show, as expected, higher serum levels of CRP in obese versus lean COVID-19 patients. Furthermore, results in Fig. 5 show a positive association between CRP and autoimmune antibodies in our cohort of lean and obese COVID-19 patients.
DISCUSSION

The results from this study show that the majority of COVID-19 patients with obesity make almost indiscernible amounts of neutralizing anti-SARS-CoV-2 antibodies, suggesting that obese individuals may be at a higher risk to respond poorly to SARS-CoV-2 infection. Our results are in disagreement with another study in which obesity was associated with increased fever and multiple severe symptoms of disease caused by SARS-CoV-2 infection but not with dysfunctional B and T cell immune responses [18]. These differences may depend on the characteristics of the different cohorts recruited in the two studies. All of our recruited participants with obesity, however, made autoimmune antibodies. We measured two different autoimmune specificities, MDA and AD, because obesity has already been shown to be associated with increased oxidative stress and lipid peroxidation (measured by MDA) [26, 27] and increased fat mass (measured by adipocyte-derived proteins released in the AT, AD) [23].

The onset of autoimmunity has been associated with viral infections, and it has been suggested that SARS-CoV-2 could be a triggering factor for the development of a rapid autoimmune, autoinflammatory disease in genetically predisposed individuals as those with high systemic interleukin-6 [28, 29], similar to what has been found in SARS-CoV, influenza, and dengue infections. In SARS-CoV patients, high levels of serum autoantibodies specific for type-2 pneumocytes have been found, and these antibodies were highly cytotoxic [30]. In influenza patients, virus-induced autoantibodies against the alveolar and glomerular basement membrane induced the autoimmune disease called Goodpasture’s syndrome [31, 32]. In dengue patients, virus-induced autoantibodies specific for endothelial cells, platelets, and coagulatory molecules lead to abnormal activation or dysfunction [33]. In all these cases, molecular mimicry between viral and host proteins may explain the cross-reactivity of induced autoantibodies.

In the current pandemic, it has been shown that serum samples of adult COVID-19 patients contain antibodies that target the tissues of infected patients instead of targeting the disease-causing virus. Anti-phospholipid, anti-type-I interferons, anti-nuclear antibodies, and rheumatoid factor have been found in a large number of COVID-19 patients and linked to severe disease as they may inactivate critical components of the antiviral response [20]. These findings have suggested that SARS-CoV-2 infection, following dissemination of the virus through the blood, may induce severe tissue damage, cell death, and release of intracellular self-antigens not previously known as disease-causing autoantigens, leading to a self-tolerance breakdown. We cannot exclude the possibility that the virus may also trigger autoimmunity through other mechanisms such as molecular mimicry between viral proteins and self-antigens or reactivation of local viral or bacterial pathogens that have not been removed due to dysfunctional immune responses in infected patients. We expected the secretion of autoimmune IgG to be increased in obese patients. However, our results have clearly shown that SARS-CoV-2 infection significantly increases serum levels of anti-MDA and anti-AD IgG antibodies more in lean than in obese patients. Serum levels of these antibodies, however, were always higher in obese versus lean COVID-19 patients. These results suggest that the infection has induced de novo autoimmune responses and self-tolerance breakdown following severe tissue damage in lean patients and demonstrates a heightened response in obese patients in which these processes are already occurring.

Early reports have shown that autoimmune IgG antibodies in adult COVID-19 patients are correlated with serum levels of CRP [20]. CRP is a marker of pathogen-driven pulmonary inflammation, embolism, and disseminated intravascular coagulation, all

![Fig. 3](image3.png) Evaluation of autoimmune IgG antibodies in serum samples of lean and obese COVID-19 patients, as compared to uninfected controls. Bars show means ± SE (standard errors) of anti-MDA (A) and anti-AD (B) IgG antibodies measured by ELISA. Mean comparisons between groups were performed by one-way ANOVA. A (F = 82.90, p < 0.0001), B (F = 32.41, p = 0.049). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

![Fig. 4](image4.png) Serum levels of CRP are higher in obese versus lean COVID-19 patients. Bars show means ± SE (standard errors) of CRP serum levels measured by ELISA. Mean comparisons between groups were performed by unpaired Student’s t-test. ***p < 0.001.
characteristics of COVID-19, and therefore CRP is a predictive marker of adverse health outcomes [34–37]. Subsequent results from the same group have shown a positive correlation between disease severity and self-tolerance breakdown, with patients with the highest serum levels of CRP also having increased amounts of autoimmune antibodies and intensities of autoreactive tests [38]. Also, CRP has been shown to correlate with blood frequencies of the subset of extrafollicular B cells that is expanded in critically ill COVID-19 patients as well as in lupus autoimmune patients [39]. These results have suggested that CRP is an effective predictor not only of disease severity but also of pathogenic autoimmune antibodies in COVID-10 patients.

We also measured serum Spike-specific IgG antibodies in our cohorts of lean and obese COVID-19 patients and uninfected controls. These antibodies were found to be significantly lower in obese as compared to lean COVID-19 patients, confirming our previously published findings that BMI is negatively associated with anti-Spike IgG serum levels [19] and consistent with the knowledge that obesity is associated with inflamming [2] and metaflammation [40] both of which are negatively associated with a functional immune system [41]. In addition, our previously published work has shown that overweight/obesity decrease the serum antibody response to the influenza vaccine in young and elderly individuals [12]. As expected, serum Spike-specific IgG antibodies were not found in lean and obese age-, gender-, and BMI-matched controls.

In conclusion, our results highlight the importance of identifying protective (neutralizing) versus pathogenic (autoimmune) antibodies in COVID-19 patients with obesity. In addition, similar autoimmune antibodies may also be secreted following COVID-19 vaccination. However, the reactogenicity of lipid nanoparticle-formulated COVID-19 mRNA vaccines in individuals with obesity, characterized by dysregulation of immune responses, has not been investigated yet. Therefore, evaluating the quality of the antibody response of obese COVID-19 patients is crucial to protect this vulnerable population at higher risk of responding poorly to infection with SARS-CoV-2 and vaccination against SARS-CoV-2 lean controls. Although our study has the limitation of having a small number of recruited participants, we believe our results have a high impact showing that obese individuals may be at a higher risk to respond poorly to SARS-CoV-2 infection.

REFERENCES
1. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059–63.
2. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamming. An evolutionary perspective on immunosenescence. Ann NY Acad Sci. 2000;908:244–54.
3. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging. 2020;12:9959–81.
4. Frasca D, Diaz A, Romero M, Garcia D, Blomberg BB. B cell immunosenescence. Annu Rev Cell Dev Biol. 2020;36:551–71.
5. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38:471–82.
6. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545–8.
7. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117:9490–6.
8. Langhi DM, Santos GC, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther. 2020;42:113–5.
9. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438–46.
10. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med. 2010;235:1412–24.
11. O’Shea D, Corrigan M, Dunne MR, Jackson R, Woods C, Gaosatwe G, et al. Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection. Int J Obes. 2013;37:1510–3.
12. Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB. Obesity decreases B cell responses in young and elderly individuals. Obesity. 2016;24:615–25.
13. Shearman CA, Almeida UA, Soares RM, Euser E, van Den Bogaard PJ, Freitas CM, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes. 2012;36:1072–7.
14. George MD, Baker JF. The obesity epidemic and consequences for rheumatoid arthritis care. Curr Rheumatol Rep. 2016;18:65.
15. Ritter A, Kreis NN, Louwen F, Yuan J. Obesity and COVID-19: molecular mechanisms linking both pandemics. Int J Mol Sci. 2020;21:5793.
16. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity affects younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71:896–7.
17. Nilles EJ, Siddiqui SM, Fischinger S, Bartsch YC, de Saint Aubin M, Zhou G, et al. Epidemiological and immunological features of obesity and SARS-CoV-2. medRxiv:2020.11.11.20229724 [Preprint]. 2020 [cited 2020 Dec 11]; [22 p. Available from: https://doi.org/10.1101/2020.11.11.20229724.
18. Frasca D, Reddy L, Cray C, Diaz A, Romero M, Kahl K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE. 2021;16:e0245424.
19. Woodruff M, Ramonell R, Lee E-H, Sanz I. Clinically identifiable autoreactivity is common in severe SARS-CoV-2 infection. medRxiv:10.1101/2020.10.21.20216192 [Preprint]. 2020 [cited 2020 Oct 28]; [8 p. Available from: https://doi.org/10.1101/2020.10.21.20216192.
20. Frasca D, Diaz A, Romero M, Blomberg BB. Phenotypic and functional characterization of double negative B cells in the blood of individuals with obesity. Front Immunol. 2021;12:616650.
21. Frasca D, Diaz A, Romero M, Garcia D, Jayram D, Thaller S, et al. Identification and characterization of adipose tissue-derived human antibodies with “anti-self” specificity. Front Immunol. 2020;11:392.
23. Frasca D, Diaz A, Romero M, Thaller S, Blomberg BB. Secretion of autoimmune antibodies in the human subcutaneous adipose tissue. PLoS ONE. 2018;13: e0197472.

24. Frasca D, Diaz A, Romero M, Thaller S, Blomberg BB. Metabolic requirements of human pro-inflammatory B cells in aging and obesity. PLoS ONE. 2019;14: e0219545.

25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.

26. Sankhla M, Sharma TK, Mathur K, Ratnesh JS, Butolia V, Gadokh AK, et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab. 2012;58:385–92.

27. Yesilbursa D, Serdar Z, Serdar A, Sarac M, Coskun S, Jale C. Lipid peroxides in obese patients and effects of weight loss on orlistat on lipid peroxides levels. Int J Obes. 2005;29:142–5.

28. Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could SARS-coronavirus-2 trigger autoimmunity and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19:102524.

29. Gagiannis D, Steinestel J, Hackenbroch C, Schreiner B, Hannemann M, Bloch W, et al. Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD). Front Immunol. 2020;11:587517.

30. Lin YS, Lin CF, Fang YT, Kuo YM, Liao PC, Yeh TM, et al. Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. Clin Exp Immunol. 2005;141:500–8.

31. Gunnarsson A, Hellmark T, Wieslander J. Molecular properties of the Goodpasture epitope. J Biol Chem. 2000;275:30844–8.

32. Reynolds J, Moss J, Duda MA, Smith J, Karkar AM, Macherla V, et al. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture’s disease. J Pathol. 2003;200:118–29.

33. Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, et al. Autoimmunity in dengue pathogenesis. J Formos Med Assoc. 2013;112:3–11.

34. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis. 2020;71:2174–9.

35. Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19. Nature. 2020;577:181–4.

36. Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21:1506–16.

37. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50:332–4.

38. Woodruff MC, Ramonell RP, Saini AS, Haddad NS, Anam FA, Rudolph ME, et al. Relaxed peripheral tolerance drives broad de novo auto-reactivity in severe COVID-19. medRxiv:10.1101/2020.10.21.20216192 [Preprint]. 2021 [cited 2021 Jul 21]; [29 p.]. Available from: https://doi.org/10.1101/2020.10.21.20216192.

39. Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21:1506–16.

40. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177–85.

41. Mayer-Pickel K. Obesity and antiphospholipid syndrome: a particular challenge in pregnancy. Obes Res. 2015;2:46–56.

AUTHOR CONTRIBUTIONS
Conceptualization, data curation, formal analysis, investigation, project administration, resources, supervision: DF, LR. Funding acquisition: DF, LR, CC, BBB. Methodology: MR, AD, KK. Validation: MR, AD, KK. Writing—original draft: DF. Writing—review and editing: DF, LR, MR, AD, CC, KK, BBB.

FUNDING
This study was supported by NIH awards AG32576, AG059719, and AG023717 and the University of Miami Department of Pathology & Laboratory Medicine.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Daniela Frasca.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021